Yoshiya Sugiura

Dr. Yoshiya Sugiura


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ATAi Takemoto
Ai Takemoto
STSatoshi Takagi
Satoshi Takagi
TUTakao Ukaji
Takao Ukaji
NGNobuhiko Gyobu
Nobuhiko Gyobu
MKMamoru Kakino
Mamoru Kakino
NFNaoya Fujita
Naoya Fujita
Purpose: Osteosarcoma, the most common bone malignancy in children, has a poor prognosis, especially when the tumor metastasizes to the lungs. Therefore, novel therapeutic strategies targeting both proliferation and metastasis of osteosarcoma are required. Podoplanin (PDPN) is expressed by various tumors and is associated with tumor-induced platelet activation via its interaction with C-type lectin-like receptor 2 (CLEC-2) on platelets. We previously found that PDPN contributed to osteosarcoma growth and metastasis through platelet activation; thus, in this study, we developed an anti-PDPN humanized antibody and evaluated its effect on osteosarcoma growth and metastasis. Experimental Design: Nine osteosarcoma cell lines and two osteosarcoma patient-derived cells were collected, and we evaluated the efficacy of the anti-DPN-neutralizing antibody PG4D2 and the humanized anti-PDPN antibody AP201, which had IgG4 framework region. The antitumor and antimetastasis effect of PG4D2 and AP201 were examined in vitro and in vivo. In addition, growth signaling by the interaction between PDPN and CLEC-2 was analyzed using phospho-RTK (receptor tyrosine kinase) array, growth assay, or immunoblot analysis under the supression of RTKs by knockout and inhibitor treatment. Results: We observed that PG4D2 treatment significantly suppressed tumor growth and pulmonary metastasis in osteosarcoma xenograft models highly expressing PDPN. The contribution of PDGFR activation by activated platelet releasates to osteosarcoma cell proliferation was confirmed, and the humanized antibody, AP201, suppressed in vivo osteosarcoma growth and metastasis without significant adverse events. Conclusions: Targeting PDPN with a neutralizing antibody against PDPN–CLEC-2 without antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity is a novel therapeutic strategy for PDPN-positive osteosarcoma.

29 July 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YSYoshiya Sugiura
Yoshiya Sugiura
RMRikuo Machinami
Rikuo Machinami
SMSeiichi Matsumoto
Seiichi Matsumoto
HKHiroaki Kanda
Hiroaki Kanda
KAKeisuke Ae
Keisuke Ae
KTKengo Takeuchi
Kengo Takeuchi
It is controversial whether patients with myxofibrosarcomas (MFSs) have better prognoses than those with undifferentiated pleomorphic sarcomas (UPSs). No useful prognostic factors have been established to date. We therefore aimed to evaluate the prognostic value of CD34 expression status in 192 patients with MFSs and UPSs. Using the log-rank test, we showed that patients with MFSs had a significantly better overall survival than did those with UPSs when defining the former as having a > 10% myxoid component (p = 0.03), but not when defining it as having a > 50% myxoid component (p = 0.1). Under the definition of MFSs as > 10% myxoid component, the log-rank test revealed that the diagnosis of the UPS and the CD34 loss (p < 0.001) were significant adverse predictors of overall survival. As per the Cox model, the CD34 loss remained an independent prognostic factor (hazard ratio = 3.327; 95% confidence interval 1.334–8.295), while the diagnosis of the UPS was a nonsignificant confounding factor (hazard ratio = 1.084; 95% confidence interval 0.679–1.727). In conclusion, CD34 expression status is a useful prognostic factor in patients with MFS and UPS, and it should be incorporated into grading systems that are used to predict outcomes.

29 May 2024 in Pathology - Research and Practice
Verified
Journal Article
Closed access
YSYoshiya Sugiura
Yoshiya Sugiura
RMRikuo Machinami
Rikuo Machinami
SMSeiichi Matsumoto
Seiichi Matsumoto
KAKeisuke Ae
Keisuke Ae
YTYu Takahashi
Yu Takahashi
KTKengo Takeuchi
Kengo Takeuchi

27 August 2022 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
PDF file
NSNaomi Shimizu
Naomi Shimizu
TITakuro Ito
Takuro Ito
SSShiji Sato
Shiji Sato
YSYoshiya Sugiura
Yoshiya Sugiura
ITIchiro Tatsuno
Ichiro Tatsuno
Treatment-related second malignancies (SMs) remain a major concern in long-term survivors of Hodgkin lymphoma (HL). In this report, the autopsy findings of a patient with HL, who was in complete remission after chemotherapy but expired of pulmonary tumor thrombotic microangiopathy (PTTM) caused by urothelial carcinoma of the renal pelvis (UCRP), were described. A 78-year-old Japanese man with a history of classical HL developed irreversible heart failure about 2.5 years after chemotherapy. The patient expired shortly after being admitted due to ineffective treatment for heart failure. However, the cause of death was not determined. The patient’s autopsy findings revealed UCRP in the left kidney, as well as infiltration around the inferior vena cava and lungs, but no HL recurrence. The primary causes of mortality were respiratory and heart failure due to PTTM. Therefore, it is essential to consider the risk of SMs and search for them in patients with HL after chemotherapy. J Clin Med Res. 2022;14(8):327-333 doi: https://doi.org/10.14740/jocmr4802

29 November 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
NONarumi Otsuka-Kamakura
Narumi Otsuka-Kamakura
YSYoshiya Sugiura
Yoshiya Sugiura
TYToshiki Yamazaki
Toshiki Yamazaki
NSNaomi Shimizu
Naomi Shimizu
NHNobuyuki Hiruta
Nobuyuki Hiruta
Cancer stem cells have the capability of self-renewal and multipotency and are, therefore, associated with tumor heterogeneity, resistance to chemoradiation therapy, and metastasis. The hypothesis that multinucleated giant cells, which often emerge following chemo- and/or radiotherapy, serve as cancer stem cells has not been fully evaluated. Although a previous study demonstrated that these cells functioned as stem cells, only low levels of Yamanaka factors were expressed, contrasting with the high expression seen from their gestated first-generation mononuclear cells. Herein, we report a case of a plasmablastic neoplasm with multinucleated giant cells that were analyzed for stemness to test the above hypothesis. The patient was a male in his 80s who had a plasmablastic neoplasm that was not easily distinguishable as plasmablastic lymphoma versus plasma cell myeloma of plasmablastic type. Lymph node biopsy showed predominant mononuclear cell proliferation with admixed multinucleated giant cells. Immunohistochemistry and in situ hybridization showed that both multinucleated and mononuclear cells had the same profile: CD138(+), light chain restriction of κ>λ, cyclin D1(+), CD68(-), EBER-ISH (+). These results suggested that both cell types were neoplastic. In accordance with the previous study, the multinucleated giant cells showed low expression of Yamanaka factors, which were highly expressed in some of the mononuclear cells. Furthermore, the multinucleated giant cells showed a much lower proliferative activity (Mib1/Ki67 index) than the mononuclear cells. Based on these results, the multinucleated giant cells were compatible with cancer stem cells. This case is expected to expand the knowledge base regarding biology of cancer stem cells.

4 August 2023 in Medicine
Verified
Journal Article
Open access
KNKensuke Namba
Kensuke Namba
DSDaiki Sakai
Daiki Sakai
HMHiroshi Mikamo
Hiroshi Mikamo
YSYuta Sugizaki
Yuta Sugizaki
YSYoshiya Sugiura
Yoshiya Sugiura
KKKaichi Kaneko
Kaichi Kaneko
Rationale: Although IgG4-related disease (IgG4-RD) can affect various organs, its association with a cardiac mass is exceptionally rare. Here, we report a case of a woman with IgG4-RD and a cardiac mass and discuss 10 similar cases reported previously. Patient concerns: A 65-year-old woman was referred to our hospital for chest discomfort and back pain. Diagnoses: In accordance with the 2019 ACR/EULAR diagnostic criteria for IgG4-RD, she was diagnosed with IgG4-RD based on dense lymphocytic infiltration on histopathology, IgG/IgG4-positive cell ratio 10/hpf IgG4-positive cells on immunostaining, and paraspinal zone soft tissue lesions in the chest. Interventions: An external pacemaker was implanted for the complete atrioventricular block on the electrocardiogram. After the diagnosis of IgG4-RD, she was treated with glucocorticoids and rituximab. Outcomes: She remains under observation without disease recurrence. Lessons: IgG4-RD are usually treated with glucocorticoids; however, in cases of a cardiac mass, life-threatening complications may occur and surgery is often needed. Combination therapy with glucocorticoids and rituximab may be effective even in patients with IgG4-RD and cardiac mass, which may avoid the need of invasive treatments, such as surgery.